Table of contents

  1. Front Matter
    Pages i-xxviii
  2. General Aspects

    1. Front Matter
      Pages 1-1
    2. Mohsen Nafar, Shiva Samavat
      Pages 3-26
    3. Athanasios Chalkias, Nicoletta Iacovidou
      Pages 27-40
    4. Deirisa Lopes Barreto, Dirk G. Struijk
      Pages 53-68
    5. Toshihiro Kobayashi
      Pages 69-82
    6. Roger G. Evans, Julian A. Smith, Bruce S. Gardiner, David W. Smith, Amanda G. Thrift, Clive N. May et al.
      Pages 83-105
    7. Grazia Serino, Fabio Sallustio, Francesco Paolo Schena
      Pages 107-138
    8. Macaulay Onuigbo, Nneoma Agbasi, Ogonna Oguejiofor, Emmanuel Okocha, Chinawaeze Aneke, Charles Odenigbo
      Pages 139-170
    9. Maria Guedes-Marques, Carlos Botelho, Pedro Maia, Teresa Mendes, Armando Carreira
      Pages 171-204
    10. Valeria Cernaro, Davide Bolignano, Antoine Buemi, Antonio Lacquaniti, Domenico Santoro, Michele Buemi
      Pages 205-227
    11. Ana Cristina Simões e Silva, André Barreto Pereira, Mauro Martins Teixeira, Antônio Lúcio Teixeira
      Pages 229-248
    12. Giuseppe Coppolino, Mariadelina Simeoni, Laura Rivoli, Chiara Summaria, Davide Bolignano
      Pages 249-268
  3. Circulating and Body Fluid Biomarkers

    1. Front Matter
      Pages 269-269
    2. Zeynep Kendi Celebi, Siyar Erdogmus, Sule Sengul
      Pages 301-325
    3. Philipp Enghard, Birgit Rudolph, Jan Klocke, Gabriela Riemekasten
      Pages 327-345
    4. Gloria Alvarez-Llamas, Irene Zubiri
      Pages 347-367

About this book

Introduction

In some countries such as the United States, kidney disease kills more people than cancers of the prostate or breast. In the United States for example there are over 15 million individuals with kidney disease. Translated to a worldwide basis, kidney disease of various aetiologies represent a significant burden on healthcare systems, affecting mortality, morbidity and also the family unit. It is therefore imperative that appropriate use is made of conventional, new and emerging biomarker platforms to aid diagnosis, treatment and an understanding of outcome measures.  Biomarkers in Kidney Disease embraces a holistic approach by combining information on different conditions that affect the kidney and the use of biomarkers. Biomarkers are described in terms of conventional, new and emerging analytes, techniques, platforms and applications. It covers the latest knowledge and trends. New platforms are described which combine advances in biomedical sciences, physics, computing and chemistry.  

Keywords

Application to prognosis Biomarkers in disease Cancer Research Discovery of biomarkers High throughput technologies

Editors and affiliations

  • Vinood B. Patel
    • 1
  • Victor R. Preedy
    • 2
  1. 1.DeptofBiomedlSci,FacltyofSci&TechnologyUniversity of Westminster LondonUnited Kingdom
  2. 2.Department of Nutrition and Dietetics,Division of Diabetes and Nutritional Sciences, Faculty of Life Science and MedicineKing’s College LondonLondonUnited Kingdom

Bibliographic information

  • DOI https://doi.org/10.1007/978-94-007-7699-9
  • Copyright Information Springer Science+Business Media Dordrecht 2016
  • Publisher Name Springer, Dordrecht
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-94-007-7698-2
  • Online ISBN 978-94-007-7699-9
  • About this book
Industry Sectors
Biotechnology
Consumer Packaged Goods
Pharma